Aardvark Therapeutics (AARD) – Research Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Aardvark Therapeutics (NASDAQ: AARD) recently:

• 11/4/2026 – Aardvark Therapeutics was downgraded by Raymond James Financial from “strong-buy” to “market perform”.
• 10/26/2026 – Aardvark Therapeutics was downgraded by Oppenheimer from “outperform” to “market perform”.
• 10/26/2026 – Aardvark Therapeutics had its price target lowered by HC Wainwright from $4.00 to $2.00. They now have a “hold” rating on the stock.
• 10/26/2026 – Aardvark Therapeutics had its price target lowered by HC Wainwright from $4.00 to $2.00. They now have a “neutral” rating on the stock.
• 10/23/2026 – Aardvark Therapeutics was given a new $2.50 price target by Royal Bank Of Canada.
• 10/19/2026 – Aardvark Therapeutics was given a new $4.00 price target by UBS Group.
• 10/19/2026 – Aardvark Therapeutics had its price target lowered by HC Wainwright from $6.00 to $4.00. They now have a “neutral” rating on the stock.
• 10/12/2026 – Aardvark Therapeutics is no longer covered by BTIG Research. They set a “neutral” rating on the stock.
• 9/29/2026 – Aardvark Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/24/2026 – Aardvark Therapeutics had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $6.00 price target on the stock.

Aardvark Therapeutics Stock Performance

NASDAQ AARD traded down $0.14 on Thursday, hitting $1.12. 161,835 shares of the stock traded hands, compared to its average volume of 361,343. The business’s fifty day moving average is $4.43 and its two-hundred day moving average is $6.21. Aardvark Therapeutics, Inc. has a 12 month low of $0.93 and a 12 month high of $16.60. The firm has a market capitalization of $24.51 million, a price-to-earnings ratio of -0.35 and a beta of 4.38.

Aardvark Therapeutics (NASDAQ:AARD) last issued its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.21. Analysts expect that Aardvark Therapeutics, Inc. will post -3.05 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the sale, the insider directly owned 35,475 shares in the company, valued at approximately $183,760.50. The trade was a 63.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 17.80% of the company’s stock.

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic diseases and other conditions involving appetite regulation. The company’s approach is based on activating bitter taste receptors in the gastrointestinal tract to stimulate the release of gut hormones associated with satiety and metabolic control.

Aardvark’s lead investigational product, ARD-101, is an orally administered, broad-spectrum bitter taste receptor agonist.